me to , love Neu if it gets to 10c .
from presentation in 2011 for those who are Neu
Market potential on NNZ-2566
•
1.5 million brain injuries per year in the US alone
•
No approved therapies
•
Assuming $12,000 for IV and $3,000 for oral as price point, total potential market value is:
•
Moderate –severe = ~$2 billion
•
Mild = ~$2 billion
•
~$500 million peak annual sales forecast (15% market penetration; hospitalized and emergency department patients only)
Competitive advantages
•
Only product to address the full range of TBI from mild to severe
•
Only competitive product currently in Phase II or beyond is progesterone
•
Two approvable outcomes: neurological function andprevention of seizures
•
Mechanism reflects broad pharmacologic actions of a naturally occurring product
•
Excellent safety profile: few serious adverse events and no known or expected drug interactions
•
Key opinion leaders (KOLs) already involved and committed
Partnership opportunities
•
US Army financing development; will be a major client (no residual rights)
•
Partnership opportunities in multiple fields and indications for oral and intravenous
Intravenous administration
TBI (moderate to severe)*
Stroke
Cardiac arrest
Perinatalasphyxia
Penetrating brain injury
Non-convulsive seizures in other CNS injuries/conditions
Oral administration
Mild TBI*
RettSyndrome/other autism spectrum disorders*
Post-stroke recovery
Prophylaxis following transient ischemic attack
Chemotherapy-induced neuropathy
Market potential of Motiva
Market potential for apathy in selected indications
16
Stroke: $1,248,000,0001
Traumatic brain injury: $840,000,000
Parkinson’s disease: $1,056,000,000
1 Assumes reimbursement at $2,400 per year
Peak annual sales forecast2(10% market penetration): ~$280 million
RettSyndrome
•
Largest single cause of intellectual disability and autism in females;
genetic disorder caused by a mutation in the MECP2gene
•
Normal infant development followed by loss of language, social contact
and motor functions, epilepsy
•
Large market potential –US = $430 million; global = $1.2 billion
http://www.stocknessmonster.com/news-item?S=NEU&E=ASX&N=641987
http://ausbiotech2011.com.au/uploads/Neuren.pdf
- Forums
- ASX - By Stock
- i'm in
me to , love Neu if it gets to 10c .from presentation in 2011...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.14 |
Change
-0.040(0.30%) |
Mkt cap ! $1.679B |
Open | High | Low | Value | Volume |
$13.20 | $13.41 | $13.12 | $4.890M | 370.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 997 | $13.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.19 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 997 | 13.140 |
1 | 1291 | 13.130 |
1 | 360 | 13.120 |
5 | 2645 | 13.110 |
10 | 9020 | 13.100 |
Price($) | Vol. | No. |
---|---|---|
13.200 | 2552 | 3 |
13.210 | 1593 | 2 |
13.220 | 2198 | 1 |
13.240 | 2198 | 1 |
13.260 | 2198 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online